Asset
AVN-944
Vertex Pharmaceuticals Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00923728 | — | withdrawn | 2009-04-01 | 2010-03-01 | Vertex Pharmaceuticals Incorporated | A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors |
| NCT00493441 | phase2 | terminated | 2007-06-01 | 2009-12-01 | Vertex Pharmaceuticals Incorporated | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer |
FDA applications (0)
This company has no applications containing this asset.